Soluble fms-like tyrosine kinase-1 antibody for diagnosis purposes (WO2010075475)

Bibliography

• Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-6
   PubMed Web of Science ®Google Scholar
• Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4
   PubMed Web of Science ®Google Scholar
• Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-4
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-30
   PubMed Web of Science ®Google Scholar
• Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9-22
   PubMed Web of Science ®Google Scholar
• Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 2006;39:469-78
   PubMedGoogle Scholar
• Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor sytem and its role under physiological and pathological conditions. Clin Sci 2005;109:227-41
   PubMed Web of Science ®Google Scholar
• Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 2006;580:2879-87
   PubMed Web of Science ®Google Scholar
• Leppanen VM, Prota AE, Jeltsch M, Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc Natl Acad Sci USA 2010;107:2425-30
   PubMedGoogle Scholar
• Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and developmentof bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
   PubMed Web of Science ®Google Scholar
• D'Andrea LD, Del Gatto A, Pedone C, Benedetti E. Peptide-based molecules in angiogenesis. Chem Biol Drug Des 2006;67:115-26
   PubMed Web of Science ®Google Scholar
• Gautier B, Goncalves V, Diana D, Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist. J Med Chem 2010;53:4428-40
   PubMedGoogle Scholar
• Morabito A, De Maio E, Di Maio M, Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006;11:753-64
   PubMed Web of Science ®Google Scholar
• Barleon B, Totzke F, Herzog C, Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem 1997;272:10382-8
   PubMed Web of Science ®Google Scholar
• Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem 2001;33:409-20
   Google Scholar
• Fisher C, Mazzone M, Jonchx B, Carmeliet P. Flt-1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008;8:942-56
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8
   PubMed Web of Science ®Google Scholar
• Verheul HMW, Hammers H, van Erp K, Vascular endothelial growth factor Trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 2007;13(14):4201-8
   PubMedGoogle Scholar
• Maitland ML, Bakris GL, Black HR, Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010;102:596-604
   PubMed Web of Science ®Google Scholar
• Wu FT, Stefanini MO, Mac Gabhann F, A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med 2010;14:528-52
   PubMedGoogle Scholar
• Onoue K, Uemura S, Takeda Y, Usefulness of soluble Fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction. Am J Cardiol 2009;104(11):1478-83
   PubMed Web of Science ®Google Scholar
• Pamukcu B, Shantsila E, Lip GYH. Soluble Fms-like tyrosine kinase-1. A novel marker for atherosclerotic progression? Circ J 2010;74:2064-5
   PubMedGoogle Scholar
• Clavel G, Bessis N, Lemeiter D, Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol 2007;124:158-64
   PubMed Web of Science ®Google Scholar
• Di Marco GS, Reuter S, Hillebrand U, The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. Am Soc Nephrol 2009;10:2235-45
   Google Scholar
• Matsunaga N, Chikaraishi Y, Izuta H, Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. Ophthalmology 2008;115:1916-22
   PubMed Web of Science ®Google Scholar
• Hornig C, Behn T, Bartsch W, Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA. J Immunol Methods 1999;226:169-77
   PubMedGoogle Scholar
• Belgore FM, Blann AD, Lip GY. Measurement of free and complexed soluble vascular endothelial growth receptor, Flt-1, in fluid samples:development and application of two new immunoassays. Clin Sc 2001;100:567-75
   PubMed Web of Science ®Google Scholar
• Block DR, Saenger AK. Pre-eclampsia, prediction, diagnosis and management beyond proteinuria and hypertension. Clin Lab News 2010;36:8-10
   Google Scholar
• Levine RJ, Maynard SE, Qian C, Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83
   PubMed Web of Science ®Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
   PubMed Web of Science ®Google Scholar
• Wiesmann C, Fuh G, Christinger HW, Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 Receptor. Cell 1997;91:695-704
   PubMed Web of Science ®Google Scholar
• Christinger HW, Fuh G, De Vos AM, Wiesmann C. The crystal structure of placental growth factor in complex domain 2 of the vascular endothelial growth factor receptor-1. J Biol Chem 2004;279:10382-8
   PubMed Web of Science ®Google Scholar
• Weeks I, Beheshti I, McCapra F, Acridinium esters as high-specific-activity labels in immunoassay. Clin Chem 1983;29:1474-9
   PubMed Web of Science ®Google Scholar
• Adamczyk M, Chen YY, Fishpaugh JR, Linker-mediated modulation of the chemiluminescent signal from N10-(3-sulfopropyl)-N-sulfonylacridinium-9-carboxamide tracers. Bioconjug Chem 2000;11:714-24
   PubMedGoogle Scholar
• Adamczyk M, Chen YY, Mattingly PG, Pan Y, Rege S. Neopentyl 3-triflyloxypropanesulfonate: a reactive sulfopropylation reagent for the preparation of chemiluminescent labels. J Org Chem 1998;63:5636-9
   Google Scholar
• Available from: http://abbottdiagnostics.com/Products/Instruments_by_Platform/web_tool/architect_i1000sr_movie_pu.cfm (Chemiflex video)
   Google Scholar
• Wu FT, Stefanini MO, Gabhann FM, Popel AS. A compartment model of VEGF in human in the presence of soluble VEGF receptor-1 acting as a ligand trap. PLoS ONE 2009;4:e5108.
   Google Scholar
• Maynard SE, Min JY, Merchan J, Excess placental soluble fms-like tyrosine kinase 1 (sFLT1) may contribute to endothelial dysfunction, hypertension and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58
   PubMed Web of Science ®Google Scholar
• Mutter WP, Karumanchi SA. Molecular mechanism of preeclampsia. Microvasc Res 2008;75:1-8.
   PubMed Web of Science ®Google Scholar
• Omland T, de Lemos JA, Sabatine MS, A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009;361:2538-47
   PubMed Web of Science ®Google Scholar
• Keller T, Zeller T, Peetz D, Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009;361:868-77
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhong Z, Huber J, Bassi R, Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clin Cancer Res 2006;12:6573-84
   PubMed Web of Science ®Google Scholar
• Lee YJ, Karl DL, Maduekwe UN, Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. Cancer Res 2010;70(21):8357-67
   PubMed Web of Science ®Google Scholar
• Tache V, LaCoursiere DY, Saleemuddin A, Parast M. Placental expression of vascular endothelial growth factor receptor-1 soluble vascular endothelial growth factor receptor-1 correlates with severity of clinical preeclampsia and villous hypermaturity. Hum Pathol 2011; In press. doi:10.1016/j.humpath.2010.11.018
   Google Scholar
• Grill S, Rusterholz C, Zanetti-Dallenbach R, Potential markers of preeclampsia – a review. Reprod Biol Endocrin 2009;7:70
   PubMed Web of Science ®Google Scholar
• Siddiqui A, Irani R, Blackwell SC, Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension 2010;55:386-93
   PubMed Web of Science ®Google Scholar
• Murphy SR, Lamarca BBD, Cockrell K, Granger JP. Role of endothelin in mediating fms-like tyrosine kianse 1 induced hypertension in pregnant rats. Hypertension 2010;55:394-8
   PubMed Web of Science ®Google Scholar
• Carty DM, Delles C, Dominiczak AF. Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med 2008;18:186-94
   PubMed Web of Science ®Google Scholar
• Hawfield A, Freedman BI. Preeclampsia: the pivotal role of placenta in its pathophysiology and markers for early detection. Ther Adv Cardiovasc Dis 2009;3:65-73
   PubMedGoogle Scholar
• Karumanchi SA, Maynard S, Sukhatme VP. Methods of treating pre-eclampsia or eclampsia. US0014197A1 (2011)
   Google Scholar